|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A biomimetic MOF nanoreactor enables synergistic suppression of intracellular defense systems for augmented tumor ablation.
|
31850458 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, the proposed AS1411@PEGMA@GQD@γ-CD-MOF composite is promising for effective DOX delivery and tumour growth inhibition both in vitro and in vivo, showing great potential for anticancer therapy.
|
31660562 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> experiments revealed that the MOF NPs could effectively inhibit melanoma growth and prevent tumor postoperative recurrence with only one X-ray irradiation after intravenous injection.
|
31293764 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results define MOF as a potential tumor suppressor in ECa participates in maintenance of ERα protein stability and regulation of ERα action.
|
30598260 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, the acidic micro-environment of tumor enhanced by the generated H+ degrades the MOF(Fe) simultaneously releasing CPT for chemotherapy and Fe3+, catalyzing H2O2 into one of the strongest reactive oxygen species (ROS) ˙OH enabling ROS-mediated therapy.
|
31361291 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings elucidate MYST1 as a tumor promoter in GBM and an EGFR activator, and may be a potential drug target for GBM treatment.
|
31691527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also elucidated that the low O<sub>2</sub>-dependent PDT of TBP-nMOF in combination with αPD-1 checkpoint blockade therapy can not only suppress the growth of primary tumor, but also stimulate an antitumor immune response for inhibiting metastatic tumor growth.
|
29584395 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effective removal of tumors in vivo further confirmed the satisfactory treatment effect of the MOF NP photosensitizer.
|
28856780 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vitro and in vivo imaging showed that the MOF@HA@ICG NPs exhibited greater cellular uptake in CD44-positive MCF-7 cells and enhanced tumor accumulation in xenograft tumors due to their targeting capability, compared to MOF@ICG NPs (non-HA-targeted) and free ICG.
|
28032505 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, MOF/hMOF was essential for anti-oxidative and anti-drug responses in vitro and regulated tumour growth and drug resistance in vivo in an Nrf2-dependent manner.
|
24571482 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (lysine) acetyltransferase 5 (KAT5), HDAC1, KDM4A, SUV39H1 and KDM6A)); TNM stage (SUV39H1, K (lysine) acetyltransferase 2B (KAT2B), lysine (K)-specific demethylase 1A (KDM1A), KDM4A, lysine (K)-specific demethylase 5C (KDM5C), K (lysine) acetyltransferase 8 (KAT8), HDAC5 and KAT5)); Nottingham Prognostic Index (KDM5C, myeloid/lymphoid or mixed-lineage leukemia (MLL), KAT8 and SET and MYND domain containing 3 (SMYD3)); receptor status (KAT5, SMYD3 and KDM1A); histological type (KAT5, KDM5C, KAT8, KDM4A and MLL); disease-free survival (SUV39H1, SMYD3, HDAC5, KDM6A, HDAC1, KDM1A, KDM4A, KAT8, KDM5C, KAT5 and MLL) and overall survival (KAT8).
|
22199269 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNAi-mediated silencing of MOF reduced both gene activation and tumor suppression by FOXP3, while both somatic mutations in clinical cancer samples and targeted mutation of FOXP3 in mouse prostate epithelial cells disrupted nuclear localization of MOF.
|
22152480 |
2011 |